<DOC>
	<DOCNO>NCT02393625</DOCNO>
	<brief_summary>This open label multi center trial determine safety efficacy ceritinib combination nivolumab ALK-positive NSCLC patient</brief_summary>
	<brief_title>Study Safety Efficacy Ceritinib Combination With Nivolumab Patients With ALK-positive Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis NSCLC carry ALK rearrangement Stage IIIB IV NSCLC relapse locally advanced metastatic NSCLC Presence least one measurable lesion define RECIST 1.1 Patients receive prior chemotherapy , ALK inhibitor , biologic therapy , investigational agent , must recover toxicity relate prior anticancer therapy grade ≤1 ( CTCAE v 4.03 ) . Patients grade ≤ 2 peripheral neuropathy grade alopecia , fatigue , nail change skin change allow enter study Patient WHO performance status 01 Presence history malignant disease NSCLC diagnose and/or require therapy within past 3 year Patients active , know suspected autoimmune disease Unable unwilling swallow tablet capsule Patient severe , acute , chronic medical condition include uncontrolled diabetes mellitus psychiatric condition laboratory abnormality opinion Investigator may increase risk associate study participation , may interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NSCLC , ALK-positive</keyword>
</DOC>